keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis in CKD

keyword
https://www.readbyqxmd.com/read/27906748/evolving-therapies-for-hepatitis-c-virus-in-chronic-kidney-disease-the-beginning-of-a-new-era
#1
Craig E Gordon, Claudia Nader
PURPOSE OF REVIEW: The current review highlights recent advances in treatment of chronic hepatitis C virus infection using new classes of agents, direct-acting antivirals (DAAs), with a focus on the evidence for their use in the setting of chronic kidney disease (CKD) stages 4-5, hemodialysis, and kidney transplantation. RECENT FINDINGS: DAA agents target-specific proteins involved in the hepatitis C virus life cycle and interrupt viral replication. Sustained virologic response, a marker of viral eradication, occurs in more than 90% of patients treated with DAA agents in the general population...
November 30, 2016: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/27858892/circulating-kidney-injury-molecule-1-is-a-novel-diagnostic-biomarker-for-renal-dysfunction-during-long-term-adefovir-therapy-in-chronic-hepatitis-b
#2
Ziyue Li, Chuan Shen, Yadong Wang, Wei Wang, Qian Zhao, Zhenzhong Liu, Yang Wang, Caiyan Zhao
The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment.We retrospectively enrolled 85 patients treated with ADV and 85 patients treated with entecavir (ETV) monotherapy, for at least 6 months. The 2 groups were matched for baseline age (± 5 years), sex, and estimated glomerular filtration rate (eGFR). Serum creatinine, cystatin C, and KIM-1 concentrations were measured, and eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin C equation, at baseline and last follow-up...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27846632/vitamin-k-metabolism-in-a-rat-model-of-chronic-kidney-disease
#3
Kristin M McCabe, Sarah L Booth, Xueyan Fu, Emilie Ward, Michael A Adams, Rachel M Holden
BACKGROUND: Patients with chronic kidney disease (CKD) have very high levels of uncarboxylated, inactive, extra-hepatic vitamin K-dependent proteins measured in circulation, putting them at risk for complications of vitamin K deficiency. The major form of vitamin K found in the liver is phylloquinone (K1). Menaquinone-4 (MK-4) is the form of vitamin K that is preferentially found in extra-hepatic tissues. METHODS: In the present study, we assessed tissue concentrations of K1 and MK-4 and the expression of vitamin K-related genes in a rat model of adenine-induced CKD...
November 16, 2016: American Journal of Nephrology
https://www.readbyqxmd.com/read/27803742/direct-acting-antivirals-for-the-treatment-of-chronic-hepatitis-c-in-patients-with-chronic-kidney-disease
#4
REVIEW
Anita Kohli, Ali Alshati, Fawaz Georgie, Richard Manch, Robert G Gish
All-oral, direct-acting antivirals (DAAs) have significantly improved the efficacy and safety of chronic hepatitis C (CHC) treatment but their effectiveness and safety among patients with chronic kidney disease (CKD) remains poorly understood. Our aim was to assess the efficacy and safety of DAAs for treatment of CKD patients. The National Library of Medicine through PubMed was searched for studies evaluating the efficacy of DAAs for the treatment of patients with CKD stages 4 or 5, as defined by the Kidney Disease Outcomes Quality Initiative guidelines [i...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27795624/rifampicin-and-anti-hypertensive-drugs-in-chronic-kidney-disease-pharmacokinetic-interactions-and-their-clinical-impact
#5
A Agrawal, S K Agarwal, T Kaleekal, Y K Gupta
Patients on dialysis have an increased incidence of tuberculosis (TB). Rifampicin, a first-line antitubercular therapy (ATT) drug, is a potent inducer of hepatic cytochrome P450 (CYP). There is potential for pharmacokinetic interaction between rifampicin and anti-hypertensives that are CYP substrates: amlodipine and metoprolol. Therefore, hypertensive patients receiving rifampicin-based ATT are at risk for worsening of hypertension. However, this hypothesis has not yet been systematically studied. In this prospective study, hypertensive CKD 5D patients with TB were followed after rifampicin initiation...
September 2016: Indian Journal of Nephrology
https://www.readbyqxmd.com/read/27793016/a-systematic-review-and-meta-analysis-does-hepatitis-c-virus-infection-predispose-to-the-development-of-chronic-kidney-disease
#6
REVIEW
Min Li, Peiyuan Wang, Chunhua Yang, Wenguo Jiang, Xiaodan Wei, Xinbo Mu, Xuri Li, Jia Mi, Geng Tian
We aimed to meta-analytically assess the predisposition of hepatitis C virus (HCV) infection to the occurrence and severity of chronic kidney disease (CKD). Two authors independently searched articles and abstracted information. Odds ratio (OR) or hazard ratio (HR) along with 95% confidence interval (CI) was converged separately in 12 longitudinal (1,972,044 subjects) and 15 cross-sectional (937,607 subjects) studies. Overall effect estimate was remarkably significant in longitudinal studies (HR, 95% CI, P: 1...
October 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27771774/usefulness-of-combination-therapy-with-daclatasvir-plus-asunaprevir-in-chronic-hepatitis-c-patients-with-chronic-kidney-disease
#7
Norihiko Morisawa, Yohei Koshima, Jun-Ichi Satoh, Yukio Maruyama, Satoru Kuriyama, Takashi Yokoo, Morimasa Amemiya
AIM: Combination therapy with Daclatasvir (DCV) plus Asunaprevir (ASV) has been proven effective in patients with chronic hepatitis C virus (HCV) infection. However, little is known as to the effect of this therapy in patients with reduced renal function. Focusing on CKD patients whose renal function has declined, the present trial addresses the efficacy and safety of this combination therapy in CKD patients with reduced estimated glomerular filtration rate (eGFR). MATERIALS AND METHODS: The study design is a single-center, retrospective longitudinal observational study enrolling 106 patients with (n = 29) or without (n = 77) CKD...
October 22, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27771699/cardiac-hepcidin-expression-associates-with-injury-independent-of-iron
#8
G Fenna van Breda, Lennart G Bongartz, Wenqing Zhuang, Rachel P L van Swelm, Jeanne Pertijs, Branko Braam, Maarten-Jan Cramer, Dorine W Swinkels, Pieter A Doevendans, Marianne C Verhaar, Roos Masereeuw, Jaap A Joles, Carlo A J M Gaillard
BACKGROUND: Hepcidin regulates systemic iron homeostasis by downregulating the iron exporter ferroportin. Circulating hepcidin is mainly derived from the liver but hepcidin is also produced in the heart. We studied the differential and local regulation of hepcidin gene expression in response to myocardial infarction (MI) and/or chronic kidney disease (CKD). We hypothesized that cardiac hepcidin gene expression is induced by and regulated to severity of cardiac injury, either through direct (MI) or remote (CKD) stimuli, as well as through increased local iron content...
2016: American Journal of Nephrology
https://www.readbyqxmd.com/read/27771693/kidney-injury-marker-1-and-neutrophil-gelatinase-associated-lipocalin-in-chronic-kidney-disease
#9
Esmeralda Castillo-Rodriguez, Raul Fernandez-Prado, Catalina Martin-Cleary, Maria Soledad Pizarro-Sánchez, Maria Dolores Sanchez-Niño, Ana Belen Sanz, Beatriz Fernandez-Fernandez, Alberto Ortiz
The current categorization of chronic kidney disease (CKD) is based on biomarkers of the glomerular function (estimated glomerular filtration rate, eGFR) and injury (urinary albumin creatinine ratio, UACR) and provides information on the risk of death and of progression of kidney disease. However, there are gaps in knowledge regarding the risk stratification of elderly patients with eGFR 45-60 ml/min/1.73 m2 and of younger patients with higher eGFR but physiological albuminuria. In this regard, most of the kidney cell mass is composed of tubules...
October 22, 2016: Nephron
https://www.readbyqxmd.com/read/27756165/relationship-between-hepatitis-b-virus-infection-and-chronic-kidney-disease-in-asian-populations-a-meta-analysis
#10
Qing-Chun Cai, Shu-Qi Zhao, Tong-Dong Shi, Hong Ren
PURPOSE: To evaluate the association of Chronic hepatitis B virus (HBV) infection and chronic kidney disease (CKD). METHODS: We searched Embase, Grateful Med, Ovid, PubMed, and the China Biological Medicine Database. A meta-analysis was performed to assess whether HBV infection plays an independent impact on the development of CKD in the general population. Relative risks of CKD (defined as reduced glomerular filtration rate or proteinuria) according to HBsAg serologic status were studied...
October 18, 2016: Renal Failure
https://www.readbyqxmd.com/read/27641990/hepatitis-c-virus-infection-and-chronic-kidney-disease-time-for-reappraisal
#11
REVIEW
Patrice Cacoub, Anne Claire Desbois, Corinne Isnard-Bagnis, Dario Rocatello, Clodoveo Ferri
Hepatitis C virus (HCV) infection is associated with tremendous morbidity and mortality due to liver complications. HCV infection is also associated with many extrahepatic manifestations including cardiovascular diseases, glucose metabolism impairment, cryoglobulinemia vasculitis, B cell non-Hodgkin lymphoma and chronic kidney disease (CKD). Many studies have shown a strong association between HCV and CKD, by reporting (i) an increased prevalence of HCV infection in patients on haemodialysis, (ii) an increased incidence of CKD and proteinuria in HCV-infected patients, and (iii) the development of membranoproliferative glomerulonephritis secondary to HCV-induced cryoglobulinemia vasculitis...
October 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27635145/an-unexpected-interaction-between-sofosbuvir-ledipasvir-and-atorvastatin-and-colchicine-causing-rhabdomyolysis-in-a-patient-with-impaired-renal-function
#12
Shyam Patel, Jennifer Andres, Kamran Qureshi
Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection. Coadministration of Sof/Led is studied only with rosuvastatin which shows significantly increased level of drug and is associated with increased risk of myopathy, including rhabdomyolysis. There is no mention of such HMG-CoA reductase inhibitor interaction as a class, as pravastatin did not have any clinically significant interaction with Sof/Led...
2016: Case Reports in Medicine
https://www.readbyqxmd.com/read/27608780/identification-and-stratification-of-diabetic-kidney-disease-using-serum-cystatin-c-and-serum-creatinine-based-estimating-equations-in-type-2-diabetes-a-comparative-analysis
#13
S Avinash, V P Singh, A K Agarwal, S Chatterjee, V Arya
BACKGROUND: Cystatin C is a low molecular weight protein produced by all nucleated human cells, with a stable production rate. Its levels are not influenced by inflammation, infections, hepatic or renal diseases, or by dietary or constitutional factors. We compared serum cystatin C and serum creatinine based predicting equations to estimate glomerular filteration rate (GFR) in type 2 diabetes mellitus, using the staging of chronic kidney disease (CKD) defined by the National Kidney Foundation...
November 2015: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27570756/evaluation-of-renal-hepatic-functional-indices-and-blood-pressure-based-on-the-progress-of-time-in-a-rat-model-of-chronic-kidney-disease
#14
Hassan Askari, Behjat Seifi, Mehri Kadkhodaee
BACKGROUND: Chronic kidney disease (CKD) is defined as either kidney damage or a decline in renal function as determined by a decreased glomerular filtration rate (GFR) for three months or longer. CKD is an important risk factor for mortality. OBJECTIVES: The aim of this study was to evaluate the effects of CKD on renal-hepatic functional indices and blood pressure in 5/6 nephrectomized (5/6 Nx) rats over the course of nine months. MATERIALS AND METHODS: Male Wistar rats were subjected to either 5/6 Nx or sham operations (n = 8)...
May 2016: Nephro-urology Monthly
https://www.readbyqxmd.com/read/27545640/-novel-treatments-for-hepatitis-c-virus-infection-in-chronic-kidney-disease
#15
Fabrizio Fabrizi, Piergiorgio Messa
Recent evidence has been accumulated showing a negative impact of chronic hepatitis C virus infection on survival in patients with chronic kidney disease. Moreover, it appears that anti-HCV positive status has been associated with an increased risk of developing chronic kidney disease in the adult general population. These reports have emphasized the need for safe and effective therapies for hepatitis C virus infection in the chronic kidney disease population. Treatment of HCV has made considerable progress with the approval of interferon-free, direct-acting antiviral drug-based combination therapies among patients with intact kidneys; but a paucity of information exists regarding chronic kidney disease patients...
July 2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/27540244/tolvaptan-use-in-severe-neonatal-autosomal-dominant-polycystic-kidney-disease-adpkd-the-pharmaceutical-challenge
#16
Kazeem Olalekan, Andy Fox, Rodney Gilbert
BACKGROUND: Unlicensed medications are used all the time in the management of diseases in childhood. Tolvaptan (Jinarc®) is a vasopressin V2-receptor antagonist licensed for use to slow the progression of cyst development and renal insufficiency of ADPKD in adults with CKD stage 1 to 3 with evidence of rapidly progressing disease. Studies of animal models implicate the antidiuretic hormone arginine vasopressin and its messenger cyclic adenosine monophosphate (cAMP) as promoters of kidney-cyst cell proliferation and luminal fluid secretion...
September 2016: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/27513517/association-of-fmo3-variants-and-trimethylamine-n-oxide-concentration-disease-progression-and-mortality-in-ckd-patients
#17
Cassianne Robinson-Cohen, Richard Newitt, Danny D Shen, Allan E Rettie, Bryan R Kestenbaum, Jonathan Himmelfarb, Catherine K Yeung
Elevated levels of circulating pro-atherogenic uremic solutes, particularly trimethylamine N-oxide (TMAO), have been implicated in cardiovascular disease development in patients with chronic kidney disease (CKD). TMAO is generated from trimethylamine (TMA) via metabolism by hepatic flavin-containing monooxygenase isoform 3 (FMO3). We determined the functional effects of three common FMO3 variants at amino acids 158, 308, and 257 on TMAO concentrations in a prospective cohort study and evaluated associations of polymorphisms with CKD progression and mortality...
2016: PloS One
https://www.readbyqxmd.com/read/27506743/imbalance-of-plasma-amino-acids-metabolites-and-lipids-in-patients-with-lysinuric-protein-intolerance-lpi
#18
Johanna Kurko, Maaria Tringham, Laura Tanner, Kirsti Näntö-Salonen, Mari Vähä-Mäkilä, Heli Nygren, Päivi Pöhö, Niina Lietzen, Ismo Mattila, Anu Olkku, Tuulia Hyötyläinen, Matej Orešič, Olli Simell, Harri Niinikoski, Juha Mykkänen
BACKGROUND: Lysinuric protein intolerance (LPI [MIM 222700]) is an aminoaciduria with defective transport of cationic amino acids in epithelial cells in the small intestine and proximal kidney tubules due to mutations in the SLC7A7 gene. LPI is characterized by protein malnutrition, failure to thrive and hyperammonemia. Many patients also suffer from combined hyperlipidemia and chronic kidney disease (CKD) with an unknown etiology. METHODS: Here, we studied the plasma metabolomes of the Finnish LPI patients (n=26) and healthy control individuals (n=19) using a targeted platform for analysis of amino acids as well as two analytical platforms with comprehensive coverage of molecular lipids and polar metabolites...
September 2016: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/27496805/peroxisome-proliferator-activated-receptor-%C3%AE-dependent-renoprotection-of-murine-kidney-by-irbesartan
#19
Makoto Harada, Yuji Kamijo, Takero Nakajima, Koji Hashimoto, Yosuke Yamada, Hisashi Shimojo, Frank J Gonzalez, Toshifumi Aoyama
Activation of renal peroxisome proliferator-activated receptor α (PPARα) is renoprotective, but there is no safe PPARα activator for patients with chronic kidney disease (CKD). Studies have reported that irbesartan (Irbe), an angiotensin II receptor blocker (ARB) widely prescribed for CKD, activates hepatic PPARα. However, Irbe's renal PPARα-activating effects and the role of PPARα signalling in the renoprotective effects of Irbe are unknown. Herein, these aspects were investigated in healthy kidneys of wild-type (WT) and Ppara-null (KO) mice and in the murine protein-overload nephropathy (PON) model respectively...
November 1, 2016: Clinical Science (1979-)
https://www.readbyqxmd.com/read/27469145/burden-of-end-stage-kidney-disease-north-africa
#20
Rashad S Barsoum
Geographical, ecological, and genetic factors result in many similarities among the six main countries of the African Sahara, including the epidemiology of kidney disease. With an average incidence of 182 and prevalence of 522 patients with end-stage kidney disease (ESKD) per million population, North Africa (NA) spends $650 million on dialysis and transplantation despite an estimated annual loss of 600,000 life years. The health burden of ESKD is not limited to its directly-related morbidity and mortality but affects even more significantly other body systems, particularly the cardiovascular system...
2016: Clinical Nephrology
keyword
keyword
26434
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"